C06再生醫療(細胞治療、基因治療、組織工程等)

Medi Post Co., Ltd.(078160)成立於2000年，總部位於韓國首爾，為一家臍帶血銀行，主要從事幹細胞與臍帶血業務，包括收集、處理及保存等。其中，異體臍帶血間質幹細胞產品已於韓國上市，用於治療退化性關節炎的膝關節軟骨缺損。另外，公司另有Pneumostem則用於治療支氣管肺發育不全之早產兒。

MEDIPOST succeeded in commercializing CARTISTEM® (for the treatment for knee degenerative osteoarthritis), the world's first allogeneic stem cell therapy product, through research and clinical development of allogeneic cord blood-derived mesenchymal stem cells (hUCB-MSCs). Additional pipelines such as SMUP-IA (an injectable treatment for early-stage knee osteoarthritis), PNEUMOSTEM (a treatment for Bronchopulmonary Dysplasia), and NEUROSTEM (a treatment for Alzheimer's disease) have completed Phase 2 clinical trials.